BEIERSDORF |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 127.85 EUR | -1.01% |
|
-2.22% | -5.78% |
| Sep. 04 | Beiersdorf: partnership with American Macro Biologics | CF |
| Aug. 30 | BEIERSDORF AG : Receives a Buy rating from JP Morgan | ZD |
Main competitors
| Revenues ($) (Y-1) | Net margin (Y-1) | Operating Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Debt/EBITDA) (Y-1) | ||
|---|---|---|---|---|---|---|---|
| 10.49B | +7.79% | +13.42% | +9.14% | +5.89% | -2.69x | ||
| 84.04B | +17.70% | +23.78% | +30.48% | +13.39% | 1x | ||
| 66.18B | +10.88% | +16.66% | +35.49% | +8.61% | 2.06x | ||
| 19.46B | +11.82% | +20.74% | +957.33% | +14.32% | 1.65x | ||
| 7.2B | +16.73% | +21.65% | +19.99% | +13.58% | -0.41x | ||
| 15.44B | +10.77% | +22.38% | +15.28% | +8.64% | 1.87x | ||
| 15.61B | +2.50% | +10.17% | +17.15% | +4.14% | 1.81x | ||
| 14.33B | +6.49% | +12.09% | +12.50% | +4.62% | 2.15x | ||
| 1.68B | -3.98% | +19.17% | +14.52% | +10.65% | 0.89x | ||
| 1.48B | +14.86% | +16.13% | +19.56% | +12.81% | -0.4x | ||
| 677M | +23.30% | +30.44% | +73.73% | +43.54% | -0.68x | ||
| 467M | +17.31% | - | +80.56% | - | - | ||
| 497M | +41.19% | +45.71% | +40.82% | +36.21% | -1.44x | ||
| 2.66B | +13.16% | +22.38% | +117.38% | +13.05% | 0.69x | ||
| 2.82B | +3.69% | +9.17% | +9.41% | +3.17% | 1x | ||
| 426M | +20.22% | +21.34% | +31.51% | +22.43% | -0.14x | ||
| 5.11B | +2.10% | +7.16% | +2.97% | +1.97% | -0.77x | ||
| 1.22B | +11.73% | +14.86% | +10.10% | +10.45% | -2.48x | ||
| 1.22B | +5.58% | +9.28% | +5.70% | +9.07% | -2.48x | ||
| Average | 13.21B | +12.31% | +18.70% | +79.14% | +13.14% | 0.09x | |
| Weighted average by Cap. | 52.33B | +14.05% | +20.73% | +114.80% | +12.05% | 1.01x |
- Stock Market
- Equities
- BEI Stock
- Sector Beiersdorf
- Financial comparisons